Long-term safety and efficacy of apomorphine infusion in Parkinson's disease (PD) patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study

被引：0
|
作者：
Katzenschlager, R.
Poewe, W.
Rascol, O. [1 ]
Trenkwalder, C. [2 ]
Deuschl, G. [3 ]
Chaudhuri, R. [4 ]
Henriksen, T. [5 ]
Van Laar, T. [6 ]
Lockhart, D. [7 ]
Lees, A. [8 ]
机构：
[1] Univ Toulouse, Dept Neurosci & Clin Pharmacol, Toulouse, France
[2] Paracelsus Elena Klin, Kassel, Germany
[3] Univ Kiel, Dept Neurol, Kiel, Germany
[4] Kings Coll Hosp NHS Fdn Trust, Natl Parkinson Fdn Int Ctr Excellence, London, England
[5] Univ Hosp Bispebjerg, Movement Disorder Clin, Copenhagen, Denmark
[6] Univ Med Ctr Groningen, Neurol, Groningen, Netherlands
[7] Britannia Pharmaceut, Reading, Berks, England
[8] Natl Hosp Neurol & Neurosurg, London, England
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR2058
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [31] Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results
    Stocchi, F
    Vacca, L
    De Pandis, MF
    Barbato, L
    Valente, M
    Ruggieri, S
    NEUROLOGICAL SCIENCES, 2001, 22 (01) : 93 - 94
  • [32] Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for Parkinson's disease (PD) Patients with Motor Fluctuations
    Pahwa, R.
    van Laar, T.
    Dashtipour, K.
    Ceresoli-Borroni, G.
    MOVEMENT DISORDERS, 2024, 39 : S349 - S349
  • [33] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [34] Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results
    F. Stocchi
    L. Vacca
    M. F. De Pandis
    L. Barbato
    M. Valente
    S. Ruggieri
    Neurological Sciences, 2001, 22 : 93 - 94
  • [35] Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson's Disease Psychosis
    Ballard, Clive
    Kreitzman, David
    Isaacson, Stuart
    Norton, James
    Demos, George
    Liu, I-Yuan
    Fernandez, Hubert
    Ilic, Tihomir
    Azulay, Jean
    Ferreira, Joaquim
    Abler, Victor
    Stankovic, Srdjan
    NEUROLOGY, 2020, 94 (15)
  • [36] Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Ballard, Clive G.
    Kreitzman, David L.
    Isaacson, Stuart
    Liu, I-Yuan
    Norton, James C.
    Demos, George
    Fernandez, Hubert H.
    Ilic, Tihomir V.
    Azulay, Jean-Philippe
    Ferreira, Joaquim J.
    Abler, Victor
    Stankovic, Srdjan
    PARKINSONISM & RELATED DISORDERS, 2020, 77 : 100 - 106
  • [37] Long-Term Efficacy and Safety of Pramipexole Extended-Release in Advanced Parkinson's Disease: An Open-Label Trial
    Schapira, Anthony
    Barone, Paolo
    Hauser, Robert
    Mizuno, Youshikuni
    Rascol, Olivier
    Busse, Michael
    Salin, Laurence
    Sohr, Mandy
    Poewe, Werner
    NEUROLOGY, 2010, 74 (09) : A349 - A350
  • [38] LONG-TERM EFFICACY OF INHALED LEVODOPA IN PARKINSON'S DISEASE SUBJECTS WITH MOTOR FLUCTUATIONS: INTERIM RESULTS OF A PHASE 3 STUDY
    Grosset, D.
    Dhall, R.
    Gurevich, T.
    Kassubek, J.
    Poewe, W.
    Rascol, O.
    Rudzinska, M.
    Cormier, J.
    Sedkov, A.
    Oh, C.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E19 - E19
  • [39] Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson's disease (PD) patients
    Isaacson, S.
    Pahwa, R.
    Tanner, C.
    Hauser, R.
    Oertel, W.
    Johnson, R.
    Felt, L.
    Stempien, M. J.
    Patni, R.
    MOVEMENT DISORDERS, 2018, 33 : S95 - S95
  • [40] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
12345